113
Views
31
CrossRef citations to date
0
Altmetric
Review

Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders

, &
Pages 1147-1158 | Published online: 09 Jan 2014

References

  • Kessler RC, Chiu WT, Demler O et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62(6), 617–627 (2005).
  • Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry62(6), 593–602 (2005).
  • Kessler RC, Brandenburg N, Lane M et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol. Med.35(7), 1073–1082 (2005).
  • Grant BF, Hasin DS, Stinson FS et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the national epidemiologic survey on alcohol and related conditions. Psychol. Med.35(12), 1747–1759 (2005).
  • Hunt C, Issakidis C, Andrews G. DSM-IV generalized anxiety disorder in the Australian national survey of mental health and well-being. Psychol. Med.32(4), 649–659 (2002).
  • Bruce SE, Machan JT, Dyck I et al. Infrequency of pure GAD: impact of psychiatric comorbidity on clinical course. Depress. Anxiety14(4), 219–225 (2001).
  • Moffitt TE, Harrington H, Caspi A et al. Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch. Gen. Psychiatry64(6), 651–660 (2007).
  • Hasin DS, Goodwin RD, Stinson FS et al. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Arch. Gen. Psychiatry62(10), 1097–1106 (2005).
  • Kendler KS, Gardner CO, Gatz M et al. The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol. Med.37(3), 453–462 (2007).
  • Andrade L, Caraveo-Anduaga JJ, Berglund P et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int. J. Methods Psychiatr. Res.12(1), 3–21 (2003).
  • Wittchen HU, Kessler RC, Beesdo K et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J. Clin. Psychiatry.63(Suppl. 8), 24–34 (2002).
  • Melartin TK, Rytsälä HJ, Leskelä US et al. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J. Clin. Psychiatry63(2), 126–134 (2002).
  • Lenze EJ, Mulsant BH, Mohlman J et al. Generalized anxiety disorder in late life: lifetime course and comorbidity with major depressive disorder. Am. J. Geriatr. Psychiatry13(1), 77–80 (2005).
  • McIntyre RS, Soczynska JK, Bottas A et al. Anxiety disorders and bipolar disorder: a review. Bipolar Disord.8(6), 665–676 (2006).
  • Gao K, Tolliver BK, Kemp DE et al. Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J. Affect. Disord.110(1–2), 167–173 (2008).
  • Grant BF, Stinson FS, Hasin DS et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the national epidemiologic survey on alcohol and related conditions. J. Clin. Psychiatry66(10), 1205–1215 (2005).
  • Simon NM, Otto MW, Wisniewski SR et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am. J. Psychiatry161(12), 2222–2229 (2004).
  • Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch. Gen. Psychiatry64(5), 543–552 (2007).
  • Goldstein BI, Levitt AJ. The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord.10(1), 67–78 (2008).
  • Compton WM, Thomas YF, Stinson FS et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry64(5), 566–576 (2007).
  • Kessler RC, DuPont RL, Berglund P et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry156(12), 1915–1923 (1999).
  • Grant BF, Hasin DS, Stinson FS et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the national epidemiologic survey on alcohol and related conditions. Psychol. Med.35(12), 1747–1759 (2005).
  • Stein MB, Heimberg RG. Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample. J. Affect. Disord.79(1–3), 161–166 (2004).
  • Munk-Jørgensen P, Allgulander C, Dahl AA et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr. Serv.57(12), 1738–1744 (2006).
  • Ansseau M, Fischler B, Dierick M et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur. Psychiatry20(3), 229–235 (2005).
  • Mittal D, Fortney JC, Pyne JM et al. Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr. Serv.57(12), 1731–1737 (2006).
  • Fava M, Alpert JE, Carmin CN et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol. Med.34(7), 1299–1308 (2004).
  • Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry165(3), 342–351 (2008).
  • DeLuca AK, Lenze EJ, Mulsant BH et al. Comorbid anxiety disorder in late life depression: association with memory decline over four years. Int. J. Geriatr. Psychiatry20(9), 848–854 (2005).
  • Otto MW, Simon NM, Wisniewski SR et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br. J. Psychiatry189, 20–25 (2006).
  • Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry163(2), 217–224 (2006).
  • Davidson JR, Bose A, Korotzer A et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety19(4), 234–240 (2004).
  • Pollack MH, Zaninelli R, Goddard A et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry62(5), 350–357 (2001).
  • Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr.9(10), 716–723 (2004).
  • Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J. Clin. Psychiatry66(10), 1321–1325 (2005).
  • Pandina GJ, Canuso CM, Turkoz I et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol. Bull.40(3), 41–57 (2007).
  • Pollack MH, Simon NM, Zalta AK et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol. Psychiatry59(3), 211–225 (2006).
  • Simon NM, Connor KM, LeBeau RT et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl.)197(4), 675–681 (2008).
  • Sheehan DV, McElroy SL, Harnett-Sheehan K et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J. Affect. Disord.115(3), 376-85 (2009).
  • Brawman-Mintzer O, Nietert PJ, Rynn M et al. Quetiapine monotherapy in patients with GAD. Presented at: 159th Annual Meeting of American Psychiatric Association. Toronto, ON, Canada, 20–25 May 2006 (New Research Abstract 634).
  • Chouinard G, Bandelow B, Ahokas A et al. Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder: a Phase III, double-blind, placebo-controlled study. Program of the 46th American College of Neuropsychopharmacology Annual Meeting. Boca Raton, FL, USA, 9–13 December 2007 (P25).
  • Joyce M, Khan A, Atkinson S et al. Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD). Presented at: 159th Annual Meeting of American Psychiatric Association. Washington, DC, USA, 3–8 May 2008 (New Research Abstract 3138).
  • Merideth C, Cutler A, Neijber A et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalized anxiety disorder. Eur. Neuropsychoparmacol.18, S499–S500 (2008).
  • Katzman M, Brawman-Mintzer O, Reyes E et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial). Presented at: 159th Annual Meeting of American Psychiatric Association. Washington, DC, USA, 3–8 May 2008 (New Research Abstract 3140).
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Version. American Psychiatric Association. Washington, DC, USA (2000).
  • World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, Switzerland (1992).
  • Hamilton M. The assessment of anxiety state by rating. Br. J. Med. Psychol.32, 50–55 (1959).
  • Andrews G, Slade T. The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis. Psychopathology35(2–3), 100–106 (2002).
  • Montgomery D. European College of Neuropsychopharmacology. ECNP Consensus Meeting March 2000. Guidelines for investigating efficacy in GAD Eur. Neuropsychopharmacol.12(1), 81–87 (2002).
  • Rickels K, Rynn MA. What is generalized anxiety disorder? J. Clin. Psychiatry62(Suppl. 11), 4–12 (2001).
  • Lee S, Tsang A, Chui H et al. A community epidemiological survey of generalized anxiety disorder in Hong Kong, Community Ment. Health J.43(4), 305–319 (2007).
  • Lee S, Tsang A, Zhang MY et al. Lifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan China. Psychol. Med.37(1), 61–71 (2007).
  • Carter RM, Wittchen HU, Pfister H et al. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress. Anxiety13(2), 78–88 (2001).
  • Cho MJ, Kim JK, Jeon HJ et al. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. J. Nerv. Ment. Dis.195(3), 203–210 (2007).
  • Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. J. Clin. Psychiatry65(Suppl. 13), 20–26 (2004).
  • Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur. Neuropsychopharmacol.15(4), 445–452 (2005).
  • Brunette MF, Noordsy DL, Xie H et al. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr. Serv.54(10), 1395–1401 (2003).
  • Gao K. Antipsychotics in the treatment of comorbid anxiety in bipolar disorder. Psychiatr. Times24(5), 68–69 (2007).
  • Olssøn I, Mykletun A, Dahl AA. Recognition and treatment recommendations for generalized anxiety disorder and major depressive episode: a cross-sectional study among general practitioners in Norway. Prim. Care Companion J. Clin. Psychiatry8(6), 340–347 (2006).
  • Lecrubier Y. Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J. Clin. Psychiatry.68(Suppl. 2), 36–41 (2007).
  • Salzman C, Goldenberg I, Bruce SE et al. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown anxiety disorders research program J. Clin. Psychiatry62(3), 149–152 (2001).
  • Goodwin RD, Gorman JM. Psychopharmacological treatment of generalized anxiety disorder and the risk of major depression. Am. J. Psychiatry159, 1935–1937 (2002).
  • Goldstein BI, Levitt AJ. Prevalence and correlates of bipolar I disorder among adults with primary youth-onset anxiety disorders. J. Affect. Disord.103(1–3), 187–195 (2007).
  • Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder. Arch. Gen. Psychiatry62, 1022–1030 (2005).
  • Gelenberg AJ, Lydiard RB, Rudolph RL et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA283(23), 3082–3088 (2000).
  • Rollman BL, Belnap BH, Mazumdar S et al. Symptomatic severity of PRIME-MD diagnosed episodes of panic and generalized anxiety disorder in primary care. J. Gen. Intern. Med.20(7), 623–628 (2005).
  • Stein DJ. Generalized anxiety disorder: rethinking diagnosis and rating. CNS Spectr.10(12), 930–934 (2005).
  • Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the british association for psychopharmacology. J. Psychopharmacol.19(6), 567–596 (2005).
  • Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry62(Suppl. 11), 53–58 (2001).
  • Allgulander C, Bandelow B, Hollander E et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr.8(8 Suppl. 1), 53–61 (2003).
  • Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders :first revision. World J. Biol. Psychiatry9(4), 248–312(2008).
  • Sheehan DV, Sheehan KH. Current approaches to the pharmacologic treatment of anxiety disorders. Psychopharmacol. Bull.40(1), 98–109 (2007).
  • Gao K, Muzina D, Gajwani P et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J. Clin. Psychiatry67(9), 1327–1340 (2006).
  • Beasley CM Jr, Potvin JH. Fluoxetine: activating and sedating effects. Int. Clin. Psychopharmacol.8(4), 271–275 (1993).
  • Baldwin DS, Montgomery SA, Nil R et al. Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol.10(1), 73–84 (2007).
  • Gao K, Ganocy SJ, Gajwani P et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J. Clin. Psychiatry69(2), 302–309 (2008).
  • Mitte K, Noack P, Steil R et al. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J. Clin. Psychopharmacol.25(2), 141–150 (2005).
  • Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol.21(8), 864–872 (2007).
  • Pollack M, Kinrys G, Krystal A et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch. Gen. Psychiatry65(5), 551–562 (2008).
  • McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities Can.J. Psychiatry46(3), 273–281 (2001).
  • Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry68(Suppl. 1), 20–27 (2007).
  • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry65, 267–272 (2004).
  • Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med.360(3), 225–235 (2009).
  • Thase ME, Jonas A, Khan A et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol.28(1), 13–20 (2008).
  • Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am. J. Psychiatry162(7), 1351–1360 (2005).
  • Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol.26(6), 600–609 (2006).
  • Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry60(11), 1079–1088 (2003).
  • Ruscio AM, Chiu WT, Roy-Byrne P et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the national comorbidity survey replication. J. Anxiety Disord.21(5), 662–676 (2007).
  • Ruscio AM, Lane M, Roy-Byrne P et al. Should excessive worry be required for a diagnosis of generalized anxiety disorder? results from the US national comorbidity survey replication. Psychol. Med.35(12), 1761–1772 (2005).
  • Mathew SJ, Amiel JM, Coplan JD et al. Open-label trial of riluzole in generalized anxiety disorder. Am. J. Psychiatry162(12), 2379–2381 (2005).
  • Mathew SJ, Price RB, Mao X et al. Hippocampal n-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol. Psychiatry63(9), 891–898 (2008).
  • Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders CNS Spectr.10(10), 820–830 (2005)

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.